LABA/ICS vs LAMA
Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS showed no clear difference in moderate to severe exacerbations: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
- Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a… 2018 · Cochrane Headline outcomes onlyOR 1.12 [0.9, 1.39]2 studies · 1580 participantsModerate